Bristol-Myers Squibb Co (BMY)
44.94
+0.20
(+0.45%)
USD |
NYSE |
May 10, 16:00
44.54
-0.40
(-0.89%)
After-Hours: 20:00
Bristol-Myers Squibb Accounts Receivable (Quarterly): 8.826B for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 8.826B |
December 31, 2023 | 8.882B |
September 30, 2023 | 8.407B |
June 30, 2023 | 8.125B |
March 31, 2023 | 7.854B |
December 31, 2022 | 8.151B |
September 30, 2022 | 8.021B |
June 30, 2022 | 7.586B |
March 31, 2022 | 7.156B |
December 31, 2021 | 7.979B |
September 30, 2021 | 7.878B |
June 30, 2021 | 7.713B |
March 31, 2021 | 7.187B |
December 31, 2020 | 7.219B |
September 30, 2020 | 6.777B |
June 30, 2020 | 6.699B |
March 31, 2020 | 7.20B |
December 31, 2019 | 6.476B |
September 30, 2019 | 4.289B |
June 30, 2019 | 4.503B |
March 31, 2019 | 4.594B |
December 31, 2018 | 4.636B |
September 30, 2018 | 4.622B |
June 30, 2018 | 4.323B |
March 31, 2018 | 4.374B |
Date | Value |
---|---|
December 31, 2017 | 4.347B |
September 30, 2017 | 4.332B |
June 30, 2017 | 4.219B |
March 31, 2017 | 4.083B |
December 31, 2016 | 3.774B |
September 30, 2016 | 3.813B |
June 30, 2016 | 3.685B |
March 31, 2016 | 3.363B |
December 31, 2015 | 2.948B |
September 30, 2015 | 2.714B |
June 30, 2015 | 2.543B |
March 31, 2015 | 2.25B |
December 31, 2014 | 2.10B |
September 30, 2014 | 1.823B |
June 30, 2014 | 1.799B |
March 31, 2014 | 1.742B |
December 31, 2013 | 1.69B |
September 30, 2013 | 1.839B |
June 30, 2013 | 1.851B |
March 31, 2013 | 1.798B |
December 31, 2012 | 1.708B |
September 30, 2012 | 1.734B |
June 30, 2012 | 1.623B |
March 31, 2012 | 3.613B |
December 31, 2011 | 2.25B |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
4.289B
Minimum
Sep 2019
8.882B
Maximum
Dec 2023
7.346B
Average
7.650B
Median
Accounts Receivable (Quarterly) Benchmarks
Amgen Inc | 6.776B |
Gilead Sciences Inc | 4.669B |
Johnson & Johnson | 14.95B |
Eli Lilly and Co | 7.886B |
2seventy bio Inc | 13.41M |